Revolution Medicines (RVMD) Other Accumulated Expenses (2019 - 2026)

Revolution Medicines' Other Accumulated Expenses history runs 8 years deep, the most recent figure standing at $3.3 million for Q1 2026.

• On a quarterly basis, Other Accumulated Expenses rose 400.92% year-over-year to $3.3 million in Q1 2026; TTM through Mar 2026 was $3.3 million, a 400.92% increase from a year earlier, with the FY2025 full-year figure at $7.9 million, up 1247.86% from the prior year.
• Other Accumulated Expenses declined to $3.3 million in Q1 2026 per RVMD's latest filing, from $7.9 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $8.2 million in Q3 2025 and bottomed at $280000.0 in Q1 2022.
• The 5-year median for Other Accumulated Expenses is $647000.0 (2022), against an average of $1.8 million.
• Across the five-year window, Other Accumulated Expenses slumped 85.04% in 2024 and jumped 1247.86% in 2025, its largest moves.
• Year by year, Other Accumulated Expenses stood at $505000.0 in 2022, then surged by 671.49% to $3.9 million in 2023, then slumped by 85.04% to $583000.0 in 2024, then soared by 1247.86% to $7.9 million in 2025, then plunged by 58.5% to $3.3 million in 2026.
• Per Business Quant, the three latest RVMD Other Accumulated Expenses figures stand at $3.3 million (Q1 2026), $7.9 million (Q4 2025), and $8.2 million (Q3 2025).